Circassia’s product is a particle-engineered formulation of the inhaled long-acting muscarinic antagonist tiotropium bromide delivered via dry powder inhaler (DPI). The product is in development as a direct substitute for Boehringer Ingelheim’s Spiriva® DPI, which is used in the treatment of chronic obstructive pulmonary disease.
Circassia is developing its Spiriva® substitute in a DPI and has completed early technical work on the particle-engineered formulation of tiotropium bromide. Following this initial success we have now progressed the product into development and intend to pursue an abbreviated regulatory route. As a result, we anticipate initiating a pharmacokinetic clinical study in H2 2017.
Pipeline status: Spiriva® substitute
Registration Study /